Skip to main content
TipRanks
Go Ultimate75% OFF

InnoCan Pharma (INNPF) AI Stock Analysis

17 Followers
INNPF

InnoCan Pharma

(Other OTC:INNPF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Strong Gross MarginsGross margins near 90% indicate favorable product economics and leave substantial room to cover operating costs as the business scales. If sustained, this profitability profile can support reinvestment in cannabinoid formulations, regulated candidates, and drug-delivery technologies.
Negative Factors
Unprofitability and Revenue DeclineThe combination of ongoing net losses and declining revenue shows that the current business has not yet converted strong gross economics into durable operating earnings. Continued top-line contraction could limit operating leverage, weaken reinvestment capacity, and delay the path to self-funded growth.

InnoCan Pharma (INNPF) vs. SPDR S&P 500 ETF (SPY)

-100%-75%-50%-25%0%25%INNPF-89.80%SPY+13.11%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$4.95M
Dividend Yield
―
Average Volume (3M)
139
Price to Earnings (P/E)
-6.2
Beta (1Y)
-0.71
Revenue Growth
-18.39%
EPS Growth
39.79%
Country
US
Employees
11
Sector
Consumer Defensive
Sector Strength
62
Industry
Medical - Pharmaceuticals

InnoCan Pharma Business Overview & Revenue Model

Company Description

InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems that integrate cannabidiol (CBD) with other pharmaceutical compounds. Its operations and development efforts span across the United States, Poland...

InnoCan Pharma Peers Comparison

Overall Rating

UnderperformOutperform
Sector (62)

Financial Indicators

INNPF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *62Neutral$20.33B14.63-3.31%3.23%1.93%-12.26%
TSE:AVCNTSE:AVCN58NeutralCAD 12.09M-3.98-65.40%―-3.32%-34.15%
TSE:LABSTSE:LABS57NeutralCAD 27.77M-9.23-7.66%―-9.31%66.84%
TSE:VMTSE:VM46NeutralCAD 26.17M-6.80-193.11%―360.63%14.21%
TSE:ATLETSE:ATLE42NeutralCAD 39.63M-0.76-2099.75%―-96.13%88.13%

* Consumer Defensive Sector Average

Performance Comparison

-50%0%50%INNPFTSE:ATLETSE:LABSTSE:VMTSE:AVCNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
INNPF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
INNPFInnocan Pharma Corporation1.09-9.75-89.94%
TSE:ATLEWillow Biosciences0.09-0.06-39.29%
TSE:LABSMedipharm Labs (Otc)0.06-0.01-14.29%
TSE:VMVoyageur Pharmaceuticals Ltd.0.12-0.03-17.86%
TSE:AVCNAvicanna Inc0.09-0.16-64.80%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.